Haploidentical Stem Cell Transplantation in Children with Benign Disorders: Improved Survival and Cost-Effective Care Over 15 Years from a Single Center in India
- 6 Downloads
We present our experience in haploidentical stem cell transplantation (haplo SCT) in children with benign disorders. We performed a retrospective study where children aged up to 18 years diagnosed to have benign disorders and underwent haplo SCT from 2002 to September 2017 were included. Of the 54 children, the most common indications were Fanconi anaemia 12 (22%), severe aplastic anaemia 8 (14%) and primary immune deficiency disorders (PID) 25 (46%). Post-transplant cyclophosphamide (PTCy) was used in 41 (75.9%) and ex vivo T depletion in 13 (24.1%). Engraftment rates were 70% with acute graft versus host disease in 36% and cytomegalovirus reactivation in 55% children. There was a statistically significant difference found between survival with siblings as donors as compared to parents (p value 0.018). Overall survival was 60% which is the 1-year survival, with 68% survival among those with PIDs. Cytokine release syndrome was noted in 12/41 (29%) of children who received T replete graft and PTCy. In children over 6 months of age, PTCy at a cost of INR 1200 provides cost effective T cell depletion comparable with TCR α/β depletion priced at INR 1200,000. Haplo SCT is feasible option for cure in children with benign disorder.
KeywordsHaploidentical stem cell transplantation Benign disorders Children
We would like to acknowledge the immense support provided by the paediatric critical care team and the infectious disease specialists in the management of these children.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Takahashi Y, Sekiya Y, Kawashima N (2014) Hematopoeitic stem cell transplantation from an alternative donor for childhood aplastic anemia: HLA haploidentical family donor vs HLA mismatched unrelated donor. Bone Marrow Transplant 49:S124Google Scholar
- 10.Hong KT, Kang HJ, Choi JY, Hong CR, Cheon JE, Park JD et al (2018) Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients. Biol Blood Marrow Transplant pii:S1083-8791(18)30383-5. https://doi.org/10.1016/j.bbmt.2018.06.034 Google Scholar